HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koutroubakis, I E Articles by Kouroumalis, E A Search for Related Content PubMed PubMed Citation Articles by Koutroubakis, I E Articles by Kouroumalis, E A Pubmed/NCBI databases Substance via MeSH

Serum laminin and collagen IV in inflammatory bowel disease

¹ Department of Gastroenterology University Hospital Heraklion, 71110 Heraklion, Crete, Greece
² Laboratory of Clinical Microbiology, University of Thessaly, 41222 Larissa, Greece

Correspondence to:
Dr I E Koutroubakis
Department of Gastroenterology, University Hospital Heraklion, PO BOX 1352, 71110 Heraklion, Crete, Greece; ktjohn{at}her.forthnet.gr Background/Aims: Laminin and collagen IV have been proposed as extracellular matrix serum markers. Because fibrosis is a major complication of inflammatory bowel disease, serum concentrations of laminin and collagen IV were measured in patients with ulcerative colitis (UC) and Crohn’s disease (CD) and compared with inflammatory and healthy controls.

Methods: Laminin and collagen IV serum concentrations were measured in 170 patients with inflammatory bowel disease (86 UC and 84 CD), in 23 patients with other causes of intestinal inflammation, and in 80 matched healthy controls using commercially available enzyme linked immunosorbent assays. Laminin and collagen IV concentrations were correlated with disease activity, type, localisation, and treatment.

Results: Mean (SD) serum laminin concentrations were 281.0 (110.1) ng/ml in patients with UC, 275.6 (106.7) ng/ml in patients with CD, 192.0 (17.8) ng/ml in healthy controls, and 198.5 (32.5) ng/ml in inflammatory controls. Mean (SD) serum collagen IV concentrations were 72.8 (22.9) ng/ml in patients with UC, 71.0 (18.2) in patients with CD, 79.8 (12.2) ng/ml in healthy controls, and 88.9 (24.6) ng/ml in inflammatory controls. There was a significant difference among the four groups (p < 0.0001) for both markers. There was a strong correlation between serum laminin, but not collagen IV, and disease activity in both diseases. No significant association was found between these markers and disease localisation or disease type.

Conclusions: Serum concentrations of laminin are increased, whereas serum concentrations of collagen IV are decreased, in patients with inflammatory bowel disease. They may be useful surrogate markers for sustained inflammation and tissue remodelling.

Keywords: collagen; Crohn’s disease; fibrosis; laminin; ulcerative colitis

Abbreviations: CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CRP, C reactive protein; HC, healthy control; IBD, inflammatory bowel disease; SCCAI, simple clinical colitis activity index; UC, ulcerative colitis

This article has been cited by other articles:

				T. L. Adair-Kirk, J. J. Atkinson, D. G. Kelley, R. H. Arch, J. H. Miner, and R. M. Senior A Chemotactic Peptide from Laminin {alpha}5 Functions as a Regulator of Inflammatory Immune Responses via TNF{alpha}-mediated Signaling J. Immunol., February 1, 2005; 174(3): 1621 - 1629. [Abstract] [Full Text] [PDF]

				A C Y Li and R P H Thompson Basement membrane components J. Clin. Pathol., December 1, 2003; 56(12): 885 - 887. [Full Text] [PDF]